195 related articles for article (PubMed ID: 19652076)
1. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.
Jeha S; Razzouk B; Rytting M; Rheingold S; Albano E; Kadota R; Luchtman-Jones L; Bomgaars L; Gaynon P; Goldman S; Ritchey K; Arceci R; Altman A; Stine K; Steinherz L; Steinherz P
J Clin Oncol; 2009 Sep; 27(26):4392-7. PubMed ID: 19652076
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Jeha S; Gaynon PS; Razzouk BI; Franklin J; Kadota R; Shen V; Luchtman-Jones L; Rytting M; Bomgaars LR; Rheingold S; Ritchey K; Albano E; Arceci RJ; Goldman S; Griffin T; Altman A; Gordon B; Steinherz L; Weitman S; Steinherz P
J Clin Oncol; 2006 Apr; 24(12):1917-23. PubMed ID: 16622268
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan.
Suzuki T; Yamauchi T; Ando K; Nagai T; Kakihana K; Miyata Y; Uchida T; Tabata Y; Ogura M
Jpn J Clin Oncol; 2013 Dec; 43(12):1177-83. PubMed ID: 24130086
[TBL] [Abstract][Full Text] [Related]
4. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic effect of clofarabine in children with relapsed or refractory acute lymphoblastic leukemia].
Suo P; Zhang LP; Wu J; Lu AD; Wang B; Zuo YX; Cheng YF; Liu GL
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jun; 15(6):444-7. PubMed ID: 23791059
[TBL] [Abstract][Full Text] [Related]
6. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Steinherz PG; Shukla N; Kobos R; Steinherz L
Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
[TBL] [Abstract][Full Text] [Related]
7. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
Hijiya N; Gaynon P; Barry E; Silverman L; Thomson B; Chu R; Cooper T; Kadota R; Rytting M; Steinherz P; Shen V; Jeha S; Abichandani R; Carroll WL
Leukemia; 2009 Dec; 23(12):2259-64. PubMed ID: 19741725
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.
Locke FL; Artz A; Rich E; Zhang Y; van Besien K; Stock W
Bone Marrow Transplant; 2010 Dec; 45(12):1692-8. PubMed ID: 20208570
[TBL] [Abstract][Full Text] [Related]
9. A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia.
Foster MC; Amin C; Voorhees PM; van Deventer HW; Richards KL; Ivanova A; Whitman J; Chiu WM; Barr ND; Shea T
Leuk Lymphoma; 2012 Jul; 53(7):1331-7. PubMed ID: 22149206
[TBL] [Abstract][Full Text] [Related]
10. Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide.
Liu AP; Lee V; Li CK; Ha SY; Chiang AK
Ann Hematol; 2016 Feb; 95(3):501-7. PubMed ID: 26666536
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.
Shukla N; Kobos R; Renaud T; Steinherz LJ; Steinherz PG
Pediatr Blood Cancer; 2014 Mar; 61(3):431-5. PubMed ID: 24115731
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Hijiya N; Thomson B; Isakoff MS; Silverman LB; Steinherz PG; Borowitz MJ; Kadota R; Cooper T; Shen V; Dahl G; Thottassery JV; Jeha S; Maloney K; Paul JA; Barry E; Carroll WL; Gaynon PS
Blood; 2011 Dec; 118(23):6043-9. PubMed ID: 21967976
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia.
Tischer J; Stemmler HJ; Engel N; Hubmann M; Fritsch S; Prevalsek D; Schulz C; Zoellner AK; Bücklein V; Hill W; Ledderose G; Hausmann A
Ann Hematol; 2013 Oct; 92(10):1379-88. PubMed ID: 23928857
[TBL] [Abstract][Full Text] [Related]
14. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Mathisen MS; Kantarjian H; Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; Borthakur G; Cortes JE; Quintás-Cardama A
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):139-43. PubMed ID: 23276886
[TBL] [Abstract][Full Text] [Related]
15. Clofarabine as a bridge to hematopoietic stem cell transplant.
Thomas CM; Ippoliti C; Roboz GJ; Feldman E; Savva D; James S; van Besien K
Leuk Lymphoma; 2017 Jan; 58(1):230-232. PubMed ID: 27240704
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.
Nabhan C; Davis N; Bitran JD; Galvez A; Fried W; Tolzien K; Foss S; Dewey WM; Venugopal P
Cancer; 2011 Apr; 117(7):1490-7. PubMed ID: 21425150
[TBL] [Abstract][Full Text] [Related]
17. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
Agura E; Cooper B; Holmes H; Vance E; Berryman RB; Maisel C; Li S; Saracino G; Tadic-Ovcina M; Fay J
Oncologist; 2011; 16(2):197-206. PubMed ID: 21273514
[TBL] [Abstract][Full Text] [Related]
18. Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.
Loeffler C; Kapp M; Grigoleit GU; Mielke S; Loeffler J; Heuschmann PU; Malzahn U; Hupp E; Einsele H; Stuhler G
Leuk Lymphoma; 2015; 56(12):3365-9. PubMed ID: 26014275
[TBL] [Abstract][Full Text] [Related]
19. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.
Jeha S; Gandhi V; Chan KW; McDonald L; Ramirez I; Madden R; Rytting M; Brandt M; Keating M; Plunkett W; Kantarjian H
Blood; 2004 Feb; 103(3):784-9. PubMed ID: 14551141
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]